Positive Phase 1 results for LTG-001, Latigo's potential best-in-class non-opioid Na v 1.8 inhibitor, demonstrated it to be well tolerated with rapid absorption Dr. Singla brings world-class expertise in analgesics, pain management, and clinical development to accelerate Company's pipeline of non-opioid pain medicines Opioid addiction is a national public health concern – 3.
75 million Americans go on to long-term chronic opioid use after low-risk surgery as up to 19% of patients exposed to opioids develop dependency THOUSAND OAKS, Calif. , Aug. 19, 2024 /PRNewswire/ -- Latigo Biotherapeutics Inc.
("Latigo") today announced positive Phase 1 results for LTG-001, its lead potential best-in-class non-opioid pain medicine candidate. In a Phase 1 first-in-human clinical trial, data showed that LTG-001 was well tolerated with rapid absorption. LTG-001 is an oral, selective Na v 1.
8 inhibitor in development to treat acute and chronic pain at its source. The Company also announced the appointment of world-renowned analgesic scientist Neil Singla , M.D.
, as chief medical officer. "Opioid addiction is a national public health concern and Latigo Bio is dedicated to being part of the solution. Latigo intends to develop non-opioid drugs that have meaningful efficacy, rapid onset of action, and superior safety to standard of care with no central nervous system effects, thereby reducing the risk of addiction," said Nima Farzan , Latigo's chief executive officer.
"These positive Phase 1 res.